Thurston, Springer, Miller, Herd & Titak, Inc. Cerevel Therapeutics Holdings, Inc. Put Options Transaction History
Thurston, Springer, Miller, Herd & Titak, Inc.
- $283 Million
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding CERE
# of Institutions
232Shares Held
151MCall Options Held
969KPut Options Held
997K-
Bain Capital Investors LLC Boston, MA65.7MShares$2.93 Billion61.94% of portfolio
-
Perceptive Advisors LLC New York, NY10.8MShares$482 Million9.58% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.56MShares$337 Million3.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.46MShares$333 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$243 Million0.01% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Market Cap $6.95B
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...